Fig. 1From: Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Physicians’ (n = 508) techniques for diagnosing NMIBC BCG-unresponsiveness (a) and biomarker tests in NMIBC patients (b)Back to article page